A 71 year old lady was reviewed because of severe hypercalcaemia. This was discovered during routine screening because of a family history of FHH and the presence of the CASR gene mutation. She was asymptomatic. She had no relevant past medical history and was not taking any medication, calcium or vitamin D supplements.
INTRODUCTION

CONCLUSIONS
An unusual case of primary hyperparathyroidism in a patient with concomitant familial hypocalciuric hypercalcaemia BES Glasgow -November 2018 Blood results indicated mild chronic kidney disease and normal vitamin D levels, raised serum calcium (3.24mmol/L), low serum phosphate (0.67mmol/L) and a slightly raised parathyroid hormone (11.9pmol/L). Her 24-hour urinary calcium excretion was inappropriately low at 2.2mmol with a fractional excretion of calcium of 0.0052 confirming hypocalciuria in the presence of hypercalcaemia. Genetic testing confirmed the presence of the CASR gene mutation [c.2444A>G, p. (Lys815Arg)]. However, the disproportionately high serum calcium level prompted further investigation. Her bone density scan showed osteopenia. An ultrasound and parathyroid MIBI scan ( Figure 1 ) detected a right lower pole parathyroid adenoma. After informed discussion she underwent parathyroidectomy (histology confirmed a parathyroid adenoma). Immediately post-operatively her calcium fell down to 2.51mmol/L (Table 1 ) and then rose back to 2.77 mmol/L. Her parathyroid hormone level also fell down to 0.8pmol/L then rose back to 2.9pmol/L, both indicating continued mild hypercalcaemia of FHH.
INVESTIGATION AND MANAGEMENT
Familial hypocalciuric hypercalcemia (FHH) is a benign condition characterized by asymptomatic hypercalcemia, relative hypocalciuria and variable parathyroid hormone levels. It is caused by a loss-of-function mutation in the calcium-sensing receptor (CASR) gene. The occurrence of both FHH and primary hyperparathyroidism (PHPT) in the same patient has rarely been described. We report an interesting case highlighting the challenges involved in diagnosis and management.
CASE Pre-operative period
Post-operative period Latest Results
Adjusted Calcium (2.2-2.6mmol/l) 3.24 2.48 2.77 Parathormone (1.4-6.2pmol/l) 11.9 0.8 2.9 Table 1 Figure 1
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